pensilina pulbere pentru suspensie orala 250 mg/5 ml
mustafa nevzat ilac sanayii a.s. - sultamicillinum - pulbere pentru suspensie orala - 250 mg/5 ml
penestin pulbere pentru solutie perfuzabila 250 mg + 250 mg
swiss parenterals pvt.ltd. - imipenemum + cilastatinum - pulbere pentru solutie perfuzabila - 250 mg + 250 mg
penestin pulbere pentru solutie perfuzabila 500 mg + 500 mg
swiss parenterals pvt.ltd. - imipenemum + cilastatinum - pulbere pentru solutie perfuzabila - 500 mg + 500 mg
pensilina im iv pulbere si solvent pentru solutie injectabila 1000 mg + 500 mg
mustafa nevzat ilac sanayii a.s. - ampicillinum + sulbactamum - pulbere si solvent pentru solutie injectabila - 1000 mg + 500 mg
tazopenil pulbere pentru solutie perfuzabila 4 g + 500 mg
magis farmaceutici spa - piperacillinum + tazobactamum - pulbere pentru solutie perfuzabila - 4 g + 500 mg
tazopenil pulbere si solvent pentru solutie injectabila 2 g + 250 mg
magis farmaceutici spa - piperacillinum + tazobactamum - pulbere si solvent pentru solutie injectabila - 2 g + 250 mg
vita grapes capsule 250 mg
eurofarmaco sa, ics - extract uscat de viță de vie viniferae (semințe) - capsule - 250 mg
vita grapes sirop 1,87 g + 2,805 g/187 ml
eurofarmaco sa, ics - extract uscat de viță de vie viniferae (semințe) + extract uscat de viță de vie viniferae (piele) - sirop - 1,87 g + 2,805 g/187 ml
z cil 1000 1000 mg pulbere pentru soluţie injectabilă
aurobindo pharma ltd - ampicillinum - pulbere pentru soluţie injectabilă - 1000 mg
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).